CL2017002413A1 - Receptor antigénico quimérico - Google Patents
Receptor antigénico quiméricoInfo
- Publication number
- CL2017002413A1 CL2017002413A1 CL2017002413A CL2017002413A CL2017002413A1 CL 2017002413 A1 CL2017002413 A1 CL 2017002413A1 CL 2017002413 A CL2017002413 A CL 2017002413A CL 2017002413 A CL2017002413 A CL 2017002413A CL 2017002413 A1 CL2017002413 A1 CL 2017002413A1
- Authority
- CL
- Chile
- Prior art keywords
- antigenic receptor
- chimeric antigenic
- chimeric
- receptor
- car
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>La presente invención se relaciona con un receptor antigénico quimérico (CAR) que comprende un dominio espaciador particular, el cual ocasiona la formación de moléculas de CAR multimérico en la superficie celular</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002413A1 true CL2017002413A1 (es) | 2018-03-16 |
Family
ID=53052211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002413A CL2017002413A1 (es) | 2015-03-23 | 2017-09-25 | Receptor antigénico quimérico |
Country Status (21)
Country | Link |
---|---|
US (1) | US11058722B2 (es) |
EP (1) | EP3274366B8 (es) |
JP (3) | JP6675417B2 (es) |
KR (1) | KR102174280B1 (es) |
CN (1) | CN107406518B (es) |
AU (1) | AU2016238583B2 (es) |
BR (1) | BR112017018252A2 (es) |
CA (1) | CA2978852C (es) |
CL (1) | CL2017002413A1 (es) |
DK (1) | DK3274366T3 (es) |
ES (1) | ES2773527T3 (es) |
GB (1) | GB201504840D0 (es) |
HU (1) | HUE047929T2 (es) |
IL (1) | IL254254B (es) |
MX (1) | MX371384B (es) |
PL (1) | PL3274366T3 (es) |
PT (1) | PT3274366T (es) |
RU (1) | RU2752880C2 (es) |
SG (1) | SG11201706940QA (es) |
WO (1) | WO2016151315A1 (es) |
ZA (1) | ZA201705682B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10975162B2 (en) | 2014-03-06 | 2021-04-13 | Autolus Limited | Chimeric antigen receptor |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
US11885806B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
JP6694875B2 (ja) | 2014-05-15 | 2020-05-20 | ナショナル ユニヴァーシティ オブ シンガポール | 改変ナチュラルキラー細胞及びその使用 |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN109689686B (zh) | 2016-10-07 | 2020-08-25 | T细胞受体治疗公司 | 使用融合蛋白进行t细胞受体重编程的组合物和方法 |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
JP7270253B2 (ja) | 2017-03-27 | 2023-05-10 | ナショナル ユニヴァーシティ オブ シンガポール | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 |
EP3601573A4 (en) * | 2017-03-29 | 2020-12-23 | Sunnybrook Research Institute | GENETICALLY MODIFIED T-LYMPHOCYTES MODULATING MOLECULES AND ASSOCIATED PROCEDURES FOR USE |
US20180325955A1 (en) | 2017-05-12 | 2018-11-15 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
JP2021500930A (ja) | 2017-11-01 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Compボディ−多価標的結合物質 |
GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
KR20210008502A (ko) | 2018-05-11 | 2021-01-22 | 크리스퍼 테라퓨틱스 아게 | 암을 치료하기 위한 방법 및 조성물 |
GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
AU2019269118A1 (en) | 2018-05-15 | 2020-12-03 | Autolus Limited | Chimeric antigen receptor |
CA3109630A1 (en) * | 2018-08-16 | 2020-02-20 | Memorial Sloan-Kettering Cancer Center | Leucine zipper-based compositions and methods of use |
CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
KR20210066865A (ko) | 2018-09-27 | 2021-06-07 | 오토러스 리미티드 | 키메라 항원 수용체 |
EP3860642A1 (en) * | 2018-10-05 | 2021-08-11 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
BR112021018627A2 (pt) | 2019-03-21 | 2021-11-23 | Regeneron Pharma | Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia |
AU2020267057A1 (en) | 2019-04-30 | 2021-11-18 | Crispr Therapeutics Ag | Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19 |
GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
WO2022204326A1 (en) * | 2021-03-24 | 2022-09-29 | The Regents Of The University Of California | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
WO2010102518A1 (zh) * | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | 一种融合蛋白多聚体 |
KR101156085B1 (ko) * | 2010-01-29 | 2012-06-20 | 국립암센터 | 4-1bb리간드(4-1bbl)오중합체 및 이의 용도 |
US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
KR101956751B1 (ko) * | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
EA201492222A1 (ru) * | 2012-05-25 | 2015-05-29 | Селлектис | Способы конструирования неаллореактивной и устойчивой к иммуносупрессии т-клетки для иммунотерапии |
AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
WO2014127261A1 (en) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Chimeric antigen receptor and methods of use thereof |
CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
AU2014368892B2 (en) * | 2013-12-20 | 2019-06-13 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
ES2767423T3 (es) | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active IP Right Grant
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en active Application Filing
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja active Active
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en active Active
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11885806B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
US11982673B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
US10975162B2 (en) | 2014-03-06 | 2021-04-13 | Autolus Limited | Chimeric antigen receptor |
US11879016B2 (en) | 2014-03-06 | 2024-01-23 | Autolus Limited | Chimeric antigen receptor |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002413A1 (es) | Receptor antigénico quimérico | |
CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
CL2017001393S1 (es) | Automovil | |
BR112018006471A2 (pt) | compostos úteis como moduladores de trpm8 | |
EA201891209A1 (ru) | Модуляторы хемокиновых рецепторов | |
CL2017001185S1 (es) | Automovil | |
DK3551926T3 (da) | Hydrogenoptankningssystem | |
CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
CL2017002099S1 (es) | Automóvil. | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
BR112017012364A2 (pt) | pré-tratamento rápido. | |
TR201910057T4 (tr) | Kauçuk bi̇leşi̇mleri̇ | |
MX2018004289A (es) | Receptores de antigenos quimericos dirigidos a psca. | |
DK3551925T3 (da) | Hydrogenoptankningssystem | |
EA201700142A1 (ru) | Полимерная композиция для слоя элемента слоя | |
EA201690245A1 (ru) | Оптимизированный способ получения композиции, содержащей изомальтулозу | |
EA201692246A1 (ru) | Способ получения 2,6-диметилбензохинона | |
CL2016000940A1 (es) | Predicción de rasgos híbridos. | |
MX369054B (es) | Detección de moléculas de ácido nucleico. | |
MX2015012340A (es) | Partículas de resinato de fenilefrina. | |
NO20130661A1 (no) | Beskyttelseshylse for påføring til en eksisterende rørledning under vann, samt tilhørende fremgangsmåte. | |
TH1401006967B (th) | โครงสร้างการยึดติดสำหรับการยึดติดชิ้นส่วนสำหรับตกเเต่งของแผงหน้าปัด | |
TH1501006528B (th) | ที่นั่งยานพาหนะ | |
TH1401003466B (th) | โครงสร้างรอบข้างของส่วนยึดติดชิ้นส่วนไฟฟ้ากับวัสดุบุหลังคา | |
TH1501004880B (th) | โครงสร้างชิ้นครอบด้านหน้าสำหรับยานพาหนะแบบนั่งขับขี่บนอาน |